Details of the Drug

General Information of Drug (ID: DMXIMQT)

Drug Name

APX-3330

Synonyms

AR-03; E-3330; APE1 inhibitors (cancer/retinopathy), ApeX Therapeutics; APX-3330 analogs (cancer/retinopathy),ApeX Therapeutics; E-3330 analogs (cancer/retinopathy), ApeX Therapeutics

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]
Ocular cancer	2D00-2D07	Discontinued in Phase 2	[2]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

Cross-matching ID

PubChem CID: 6439397
TTD ID: D0U8XW

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
AP endonuclease 1 (APEX1)	TTHGL48	APEX1_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035303)
3	Inhibition of APE1/Ref-1 redox activity with APX3330 blocks retinal angiogenesis in vitro and in vivo. Vision Res. 2011 Jan;51(1):93-100.